The Rich Heterogeneity of Platelets and Its Vital Shifts Across Disease States – RPTH
Research and Practice in Thrombosis and Haemostasis (RPTH) shared a post on LinkedIn about a recent article by Deepa Gautam, adding:
“Are all platelets the same?
Or are we missing critical biology hiding in plain sight?
We still rely on platelet count and MPV in both research and the clinic.
But this study shows that platelets are far from uniform and that heterogeneity systematically shifts across disease states.
Here’s what this paper delivers.
Using a 12-marker spectral flow cytometry panel pus high – dimensional clustering (PlateletProfiler), the authors map platelet states at single – cell resolution.
Platelets exist along an activation continuum, not just ‘resting vs activated’:
- Resting
- Primed
- Aggregatory
- Procoagulant
Disease reshapes platelet composition across models:
- Inflammation (LPS) – expansion of primed plus aggregatory platelets
- Jak2V617F (MPN) – increase in aggregatory plus procoagulant platelets
- Cancer – enrichment of procoagulant platelets
Key mechanistic signal, all models showed:
- Increased reticulated (young) platelets
- Upregulation of activation plus immune markers (e.g., PD-L1, CD154)
This suggests:
- Accelerated thrombopoiesis
- Functionally ‘pre-activated’ circulating platelets
- A link between platelet biology and immune modulation
Why this matters
We’ve been treating platelets as a homogeneous population.
This framework opens the door to:
- Subpopulation-specific biomarkers
- More precise antiplatelet strategies
- Better mechanistic links between platelets, inflammation, and cancer”
Title: Characterizing mouse platelet heterogeneity across diverse disease models using spectral flow cytometry and high-dimensional analysis
Authors: Deepa Gautam, Emily M. Clarke, Rebecca L. Zon, Margaret R. Smith-Oliver, Avinash Kumar 5, Megan E. Sullivan, Panagiotis Karagiannis, Harvey G. Roweth, Elisabeth Battinelli
Read the Full Article on RPTH

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin